科拓生物
(300858)
| 流通市值：34.94亿 | | | 总市值：47.03亿 |
| 流通股本：1.96亿 | | | 总股本：2.63亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 209,112,403.69 | 99,696,317.1 | 97,785,478.66 | 62,560,187.59 |
| 交易性金融资产 | 525,731,156.32 | 110,206,205.65 | 100,787,199.86 | 201,319,515.59 |
| 应收票据及应收账款 | 78,749,012.25 | 69,064,593.99 | 65,945,547.23 | 69,527,425.35 |
| 其中：应收票据 | - | - | 699,613.2 | 454,632 |
| 应收账款 | 78,749,012.25 | 69,064,593.99 | 65,245,934.03 | 69,072,793.35 |
| 应收款项融资 | 656,400 | 478,481.67 | - | - |
| 预付款项 | 10,681,436.35 | 5,665,002.53 | 18,364,191.05 | 18,739,421.1 |
| 其他应收款合计 | 1,094,289.88 | 1,129,214.96 | 755,895.89 | 717,893.35 |
| 存货 | 38,303,180.4 | 46,466,130.35 | 48,283,886.58 | 44,074,348.55 |
| 一年内到期的非流动资产 | 32,562,619.85 | 620,361,591.34 | 616,302,970.34 | 611,792,841.34 |
| 其他流动资产 | 23,734,368.02 | 24,270,312.44 | 27,103,490.21 | 23,717,743.43 |
| 流动资产合计 | 920,624,866.76 | 977,337,850.03 | 975,328,659.82 | 1,032,449,376.3 |
| 非流动资产: | | | | |
| 长期股权投资 | 24,581,958.4 | 22,800,486.77 | 22,250,937.77 | 22,275,954.85 |
| 其他权益工具投资 | 1,284,186 | 1,284,186 | 1,231,554 | 1,231,554 |
| 固定资产 | 363,698,928.55 | 371,284,047.5 | 353,548,257.71 | 359,791,265.48 |
| 在建工程 | 528,737,282.76 | 502,864,828.5 | 341,594,975.74 | 298,862,799.55 |
| 使用权资产 | 3,319,096.46 | 3,616,493.29 | 3,357,093.22 | 3,137,825.62 |
| 无形资产 | 59,419,813.29 | 60,102,231.46 | 60,216,443.67 | 54,928,838.76 |
| 商誉 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 |
| 长期待摊费用 | 1,524,129.53 | 1,681,798.1 | 7,584,129.45 | 1,681,798.1 |
| 递延所得税资产 | 14,672,176.73 | 13,009,728.75 | 4,616,674.21 | 3,664,282.98 |
| 其他非流动资产 | 107,533,251.41 | 63,013,905.76 | 169,217,394.43 | 163,655,281.42 |
| 非流动资产合计 | 1,106,684,157.56 | 1,041,571,040.56 | 965,530,794.63 | 911,142,935.19 |
| 资产总计 | 2,027,309,024.32 | 2,018,908,890.59 | 1,940,859,454.45 | 1,943,592,311.49 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 85,707,577.97 | 88,075,821.71 | 50,061,581.78 | 48,939,745.89 |
| 应付账款 | 85,707,577.97 | 88,075,821.71 | 50,061,581.78 | 48,939,745.89 |
| 合同负债 | 16,739,014.1 | 14,065,235.94 | 18,397,271.14 | 19,701,332.02 |
| 应付职工薪酬 | 5,167,405.33 | 14,689,627.9 | 4,997,194.73 | 4,988,163.05 |
| 应交税费 | 8,253,019.7 | 7,793,515.25 | 7,641,035.5 | 5,629,987.23 |
| 其他应付款合计 | 875,606.44 | 1,031,094.9 | 907,260.13 | 42,441,916.33 |
| 应付股利 | - | - | - | 39,524,267.7 |
| 一年内到期的非流动负债 | 808,304.92 | 785,068.13 | 700,988.78 | 605,390.96 |
| 其他流动负债 | 1,503,149.94 | 1,159,916.63 | 1,541,539.04 | 1,841,318.65 |
| 流动负债合计 | 119,054,078.4 | 127,600,280.46 | 84,246,871.1 | 124,147,854.13 |
| 非流动负债: | | | | |
| 租赁负债 | 2,437,953.01 | 2,800,876.52 | 2,681,060.32 | 2,671,412.53 |
| 递延收益 | 46,186,004.35 | 43,825,685.55 | 26,194,783.73 | 24,105,633.19 |
| 递延所得税负债 | 1,851,606.65 | 1,853,961.25 | 1,461,265.95 | 1,418,810.52 |
| 非流动负债合计 | 50,475,564.01 | 48,480,523.32 | 30,337,110 | 28,195,856.24 |
| 负债合计 | 169,529,642.41 | 176,080,803.78 | 114,583,981.1 | 152,343,710.37 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 263,495,118 | 263,495,118 | 263,495,118 | 263,495,118 |
| 资本公积 | 1,105,307,155.46 | 1,105,307,155.46 | 1,107,041,979.46 | 1,107,041,979.46 |
| 其他综合收益 | 6.87 | 11.51 | -21.25 | 41.21 |
| 盈余公积 | 59,209,225.34 | 59,209,225.34 | 57,702,020.68 | 57,702,020.68 |
| 未分配利润 | 429,767,876.24 | 414,816,576.5 | 398,036,376.46 | 363,009,441.77 |
| 归属于母公司股东权益合计 | 1,857,779,381.91 | 1,842,828,086.81 | 1,826,275,473.35 | 1,791,248,601.12 |
| 股东权益合计 | 1,857,779,381.91 | 1,842,828,086.81 | 1,826,275,473.35 | 1,791,248,601.12 |
| 负债和股东权益合计 | 2,027,309,024.32 | 2,018,908,890.59 | 1,940,859,454.45 | 1,943,592,311.49 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-22 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |